Antiphospholipid antibodies in end-stage renal disease: A systematic review and meta-analysis.
Antiphospholipid antibodies
Fistula occlusion
end-stage renal disease
Journal
Hemodialysis international. International Symposium on Home Hemodialysis
ISSN: 1542-4758
Titre abrégé: Hemodial Int
Pays: Canada
ID NLM: 101093910
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
18
10
2019
revised:
08
05
2020
accepted:
10
05
2020
pubmed:
12
6
2020
medline:
20
3
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
The relationship between autoimmune hemolytic anemia and antiphospholipid antibodies (aPL) and/or antiphospholipid syndrome has never been systematically addressed. Systematic review of EMBASE and PubMed databases performed according to PRISMA guidelines from inception to March 2020; meta-analysis performed by Peto's odds ratio for rare events. Forty-five studies with different outcomes met the inclusion/exclusion criteria. The pooled prevalence (PP) of IgG anticardiolipin antibodies (aCL) positivity was greater in end-stage renal disease (ESRD) than controls (20.2% vs. 2.6%, P = 0.001, I Lupus anticoagulant relates to ESRD regardless of management whereas IgG aCL relates specifically to ESRD on hemodialysis, but only lupus anticoagulant associates with fistula occlusion. The expression of aPL as patients positive for aPL rather than as titers precludes further assumptions on the relationship.
Substances chimiques
Antibodies, Antiphospholipid
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-396Informations de copyright
© 2020 International Society for Hemodialysis.
Références
Limper M, Scirè CA, Talarico R, et al. Antiphospholipid syndrome: State of the art on clinical practice guidelines. RMD Open. 2018;4:e000785.
de Azevedo FVA, Maia DG, de Carvalho JF, Rodrigues CEM. Renal involvement in antiphospholipid syndrome. Rheumatol Int. 2018;38:1777-1789.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med. 2009;514:65-94.
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-analyses. Ottawa Hospital Research Institute. Available from:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
Catharina Brockhaus A, Grouven U, Bender R. Performance of the Peto odds ratio compared to the usual odds ratio estimator in the case of rare events. Biom J. 2016;58:1428-1444.
Choi SW, Lam DMH. Funnels for publication bias-Have we lost the plot? Anaesthesia. 2016;71:338-341.
Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. Clin Epidemiol. 2000;253:477-484.
Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. Br Med J. 2006;333:597-600.
Quereda C, Pardo A, Lamas S, et al. Lupus-like in vitro anticoagulant activity in end-stage renal disease. Nephron. 1988;49:39-44.
Grönhagen-Riska C, Teppo AM, Helanterä A, Honkanen E, Julkunen H. Raised concentrations of antibodies to cardiolipin in patients receiving dialysis. BMJ. 1990;300:1696-1697.
García-Martín F, De Arriba G, Carrascosa T, et al. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant. 1991;6:543-547.
Chew SL, Lins RL, Daelemans R, Zachee P, De Clerck LS, Vermylen J. Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant. 1992;7:1194-1198.
Matsuda J, Saitoh N, Gohchi K, Tsukamoto M, Nakamura K, Kinoshita T. Beta 2-glycoprotein I-dependent and-independent anticardiolipin antibody in patients with end-stage renal disease. Thromb Res. 1993;72:109-117.
Phillips AO, Jones HW, Hambley H, Hillis AN, Hendry BM. Prevalence of lupus anticoagulant and anticardiolipin antibodies in haemodialysis patients. Nephron. 1993;65:350-353.
Sitter T, Spannagl M, Schiffl H. Anticardiolipin antibodies and lupus anticoagulant in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus. Ann Hematol. 1992;65:79-82.
Sallam S, Wafa E, el-Gayar A, Sobh M, Salama O. Anticardiolipin antibodies in children on chronic haemodialysis. Nephrol Dial Transplant. 1994;9:1292-1294.
Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: Relationship between lupus anticoagulant and thrombosis. Kidney Int. 1995;48:794-800.
Oymak O, Erdem Y, Yalcin AU, Yasavul U, Turgan C, Cağlar S. Increased prevalence of anticardiolipin antibodies in renal transplant recipients. Nephron. 1995;71:469-470.
Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis. 1995;26:347-352.
Petersen LJ, Ringsdal VS, Ladefoged SD, Baslund B, Hansen PR. Anticardiolipin antibodies and lipoprotein (a) levels in patients with chronic renal failure treated with dialysis: Associations with atherothrombotic disease. Int J Artif Organs. 1996;19:339-342.
Ferlazzo B, Barrile A, Bonanno D, et al. Anticardiolipin antibodies in hemodialysis patients and in renal transplant recipients: Prevalence and significance. Recenti Prog Med. 1998;89:434-437.
George J, Aron A, Levy Y, et al. Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events. Hum Antibodies. 1999;9:125-131.
Ozdemir N, Güz G, Sezer S, Haberal A, Ayaz H, Haberal M. Anticardiolipin antibodies in hemodialysis patients. Transplant Proc. 1999;31:3388-3389.
Le Sar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg. 1999;189:73-79.
Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol. 1999;51:116-121.
Fabrizi F, Sangiorgio R, Pontoriero G, et al. Antiphospholipid (aPL) antibodies in end-stage renal disease. J Nephrol. 1999;12:89-94.
Haviv YS. Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: Cause or effect? Nephron. 2000;86:447-454.
Palomo I, Pereira J, Alarcón M, Vasquez M, Pierangeli S. Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis. Nephron. 2002;92:957-958.
Jamshid R, Reza SA, Abbas G, Raha A. Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients. Int Urol Nephrol. 2003;35:275-282.
Nampoory MR, Das KC, Johny KV, et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis. 2003;42:797-805.
Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol. 2004;24:495-501.
Cengiz K, Kilic M, Bedir A. Apolipoprotein and anticardiolipin antibodies in patients with renal amyloidosis. Nephrology (Carlton). 2004;9:118-121.
Gültekin F, Alagözlü H, Candan F, Nadir I, Bakici MZ, Sezer H. The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis. ASAIO J. 2005;51:162-164.
Chuang FR, Chen TC, Yang CC, et al. IgM-anticardiolipin antibody and vascular access thrombosis in chronic hemodialysis patients. Ren Fail. 2005;27:25-30.
Chuang FR, Chang HW, Lin CL, et al. Anticardiolipin antibody and Taiwanese chronic haemodialysis patients with recurrent vascular access thrombosis. Int J Clin Pract. 2005;59:785-790.
Antoniadi G, Eleftheriadis T, Liakopoulos V, et al. Effect of 1-year oral alpha-tocopherol administration on anticardiolipin antibodies in hemodialysis patients. Ren Fail. 2005;27:193-198.
Yazeed SA, El-Ghaffar NA, Kand Y, El-Ghobary A. Antiphospholipid antibodies in Egyptian patients with chronic renal failure. J Med Sci. 2006;6:468-473.
Roozbeh J, Serati AR, Malekhoseini SA. Arteriovenous fistula thrombosis in patients on regular hemodialysis: A report of 171 patients. Arch Iran Med. 2006;9:26-32.
Lee CH, Wang IK, Chen TC, et al. Anticardiolipin antibodies and vascular access thrombosis in Taiwanese haemodialysis patients with chronic hepatitis C: A retrospective study. Int J Clin Pract. 2006;60:1591-1595.
Skouri H, Gandouz R, Abroug S, et al. A prospective study of the prevalence of heparin-induced antibodies and other associated thromboembolic risk factors in pediatric patients undergoing hemodialysis. Am J Hematol. 2006;81:328-334.
Fernández-Abreu MC, Diez-Ewald M, Briceño S, Torres-Guerra E, Rodríguez Z, Fernández N. Frequency and clinical implications of lupus anticoagulant in patients with terminal chronic renal failure in hemodialysis. Invest Clin. 2007;48:69-79.
Serati AR, Roozbeh J, Sagheb MM. Serum LDL levels are a major prognostic factor for arteriovenous fistula thrombosis (AVFT) in hemodialysis patients. J Vasc Access. 2007;8:109-114.
Danis R, Ozmen S, Akin D, et al. Thrombophilias and arteriovenous fistula dysfunction in maintenance hemodialysis. J Thromb Thrombolysis. 2009;27:307-315.
Ucar E, Kuvandik G, Sert M, Kuvandik C, Temizkan A, Borazan A. Are the anticardiolipin antibodies a risk factor for coronary artery disease in chronic renal failure patients? Ren Fail. 2008;30:791-795.
Sfar I, Elbeldi A, Aouini S, et al. Prevalence of autoantibodies in a Tunisian cohort of hepatitis C virus infected dialysis patients. Arch Inst Pasteur Tunis. 2009;86:63-68.
Ozmen S, Danis R, Akin D, Batun S. Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure. Clin Nephrol. 2009;72:193-198.
Ghisdal L, Broeders N, Wissing KM, et al. Thrombophilic factors in stage V chronic kidney disease patients are largely corrected by renal transplantation. Nephrol Dial Transplant. 2011;26:2700-2705.
Serrano A, García F, Serrano M, et al. IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int. 2012;81:1239-1244.
Hadhri S, Rejeb MB, Belarbia A, Achour A, Skouri H. Hemodialysis duration, human platelet antigen HPA-3 and IgA isotype of anti-β2-glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients. Thromb Res. 2013;131:e202-e209.
Salmela B, Hartman J, Peltonen S, Albäck A, Lassila R. Thrombophilia and arteriovenous fistula survival in ESRD. Clin J Am Soc Nephrol. 2013;8:962-968.
Bataille S, Burtey S, Decourt A, et al. Antiphospholipids antibodies and hemodialysis: a frequent association linked to arteriovenous fistula thrombosis. Nephrol Ther. 2015;11:27-33.
Broder A, Mowrey WB, Kim M, et al. Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: A retrospective cohort study. Rheumatology. 2016;55:817-825.
Fadel FI, Elshamaa MF, Abdel-Rahman SM, et al. Coagulation, thrombophilia and patency of arteriovenous fistula in children undergoing haemodialysis compared with healthy volunteers: A prospective analysis. Blood Coagul Fibrinolysis. 2016;27:190-198.
Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med. 1996;100:530-536.
Ames PRJ, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V, Anggard EE. Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost. 1998;79:447-449.
Ames PRJ, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies-A crucial role for acquired free protein S deficiency. Thromb Haemost. 1996;76:190-194.
Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48:752-760.
Merashli M, Alves J, Ames PRJ. Clinical relevance of antiphospholipid antibodies in systemic sclerosis: A systematic review and meta-analysis. Semin Arthritis Rheumatol. 2017;46:615-624.
Vaarala O, Alfthan G, Jauhiainen M, et al. Cross reaction between antibodies to oxidized low density lipoproteins and to cardiolipin in lupus erythematosus. Lancet. 1993;341:923-925.
Ikematsu H, Schettino EW, Casali P. Structure of the VH-D-JH segments of human natural polyreactive IgM and IgG antibodies. Use of germline or somatically mutated forms of commonly expressed VH genes. Ann NY Acad Sci. 1995;764:362-369.
Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812-818.
Fattal I, Shental N, Ben-Dor S, et al. Guanine polynucleotides are self-antigens for human natural autoantibodies and are significantly reduced in the human genome. Immunology. 2015;146:401-410.
Rolla R, Vidali M, Serino R, Pergolini P, Albano E, Bellomo G. Antibodies against oxidized phospholipids in laboratory tests exploring lupus anti-coagulant activity. Clin Exp Immunol. 2007;149:63-69.
Cerrillos-Gutiérrez JI, Miranda-Díaz AG, Preciado-Rojas P, et al. The beneficial effects of renal transplantation on altered oxidative status of ESRD patients. Oxid Med Cell Longev. 2016;2016:5757645.
Ames PRJ, Merashli M, Bucci T, Gentile F, Delgado-Alves J. Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis. Semin Arthritis Rheumatol. 2019;48:1041-1052. https://doi.org/10.1016/j.semarthrit.2018.10.016.
Hu H, Patel S, Hanisch JJ, et al. Future research directions to improve fistula maturation and reduce access failure. Semin Vasc Surg. 2016;29:153-171.
Godo S, Shimokawa H. Divergent roles of endothelial nitric oxide synthases system in maintaining cardiovascular homeostasis. Free Radic Biol Med. 2017;109:4-10.
Ulrich V, Konaniah ES, Lee WR, et al. Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice. J Am Heart Assoc. 2014;3:e001369.
Ames PRJ, Batuca JR, Ciampa A, Iannaccone L, Delgado AJ. Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome. J Rheumatol. 2010;37:2523-2530.
Kopel T, Kaufman JS, Hamburg N, Sampalis JS, Vita JA, Dember LM. Endothelium-dependent and -independent vascular function in advanced chronic kidney disease. Clin J Am Soc Nephrol. 2017;12:1588-1594.
Ames PRJ, Matsuura E, Batuca JR, et al. High-density lipoprotein inversely relates to its specific autoantibody favouring oxidation in thrombotic primary antiphospholipid syndrome. Lupus. 2010;19:711-716.
Ambrosino P, Lupoli R, Di Minno A, Iervolino S, Peluso R, Di Minno MN. Markers of cardiovascular risk in patients with antiphospholipid syndrome: A meta-analysis of literature studies. Ann Med. 2014;46:693-702.
Lam EY, Taylor LM Jr, Landry GJ, Porter JM, Moneta GL. Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations. J Vasc Surg. 2001;33:976-982.